Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact

Publication date

2017

Authors

de Vrueh, Remco L A
Crommelin, DaanISNI 0000000115782349

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

Abstract

Public Private Partnerships (PPPs) are multiple stakeholder partnerships designed to improve research efficacy. We focus on PPPs in the biomedical/pharmaceutical field, which emerged as a logical result of the open innovation model. Originally, a typical PPP was based on an academic and an industrial pillar, with governmental or other third party funding as an incentive. Over time, other players joined in, often health foundations, patient organizations, and regulatory scientists. This review discusses reasons for initiating a PPP, focusing on precompetitive research. It looks at typical expectations and challenges when starting such an endeavor, the characteristics of PPPs, and approaches to assessing the success of the concept. Finally, four case studies are presented, of PPPs differing in size, geographical spread, and research focus.

Keywords

key drivers, performance evaluation, public-private-partnerships, R&D business models, SDG 9 - Industry, Innovation, and Infrastructure

Citation

de Vrueh, R L A & Crommelin, D J A 2017, 'Reflections on the Future of Pharmaceutical Public-Private Partnerships : From Input to Impact', Pharmaceutical Research, vol. 34, no. 10, pp. 1985-1999. https://doi.org/10.1007/s11095-017-2192-5